# Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma

> **NCT01370317** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 27 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** MK-1029
- **DRUG:** Placebo for MK-1029

## Key facts

- **NCT ID:** NCT01370317
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06-01
- **Primary completion:** 2011-12-27
- **Final completion:** 2011-12-27
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2019-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01370317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01370317, "Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01370317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*